NCT06650709 (NEOCATS) is a Phase 2 clinical trial of Olaparib in Ovarian Cancer Stage IV, sponsored by British Columbia Cancer Agency.

Who is sponsoring NCT06650709?

NCT06650709 is sponsored by British Columbia Cancer Agency.

What drugs are being tested in NCT06650709?

Interventions in NCT06650709: Olaparib, Bevacizumab, Durvalumab.

What condition does NCT06650709 study?

NCT06650709 studies Ovarian Cancer Stage IV.

Is NCT06650709 still recruiting?

NCT06650709 is currently not yet recruiting. Last updated 23 October 2024.

Last reviewed 2024-10-23 · How we verify

NCT06650709: NEOCATS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study

Not yet recruiting Phase 2 Last updated 23 October 2024

What this trial tests

Phase 2 trial testing Olaparib in Ovarian Cancer Stage IV in 40 participants. Not yet recruiting.

Timeline

1 November 2024

Primary endpoint
1 May 2026

1 November 2028

Quick facts

Lead sponsor	British Columbia Cancer Agency
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	1 November 2024
Primary completion	1 May 2026
Estimated completion	1 November 2028

Drugs / interventions tested

Olaparib (olaparib) — full drug profile →
Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
Durvalumab — full drug profile →

Conditions studied

Ovarian Cancer Stage IV — all drugs for Ovarian Cancer Stage IV →

Sponsor

British Columbia Cancer Agency

Who can join

18 and older, female only, with Ovarian Cancer Stage IV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this phase 2 clinical trial is to learn if the three treatments olaparib, durvalumab and bevacizumab can treat participants with a diagnosis of stage 4 high grade serous ovarian cancer that is too advanced to undergo upfront surgery. The main questions it aims to answer are: Is the treatment able to shrink the cancer sufficiently for participants to undergo surgery? Is the combination of treatments safe in this neoadjuvant (before surgery) setting? This is a single arm study with no comparator arm. Participants will receive the treatment up to 3 cycles with each drug given as follows in a 28-day cycle: Olaparib orally on a twice daily continuous dosing schedule Durvalumab given intravenously on day 1 Bevacizumab given intravenously on day 1 and 15 (Day 15 omitted in C3) Participants will be assessed throughout the study for safety and efficacy endpoints

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Olaparib

Trials testing the same drug.

NCT05522491 — Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Br · Phase 2 · not yet recruiting
NCT05128734 — Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) · Phase 2 · not yet recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07407452 — Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Che · Phase 2 · not yet recruiting
NCT06915025 — Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemo · Phase 3 · recruiting

Other recruiting trials for Ovarian Cancer Stage IV

Currently open trials in the same condition.

NCT07067255 — Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer · Phase 1, PHASE2 · recruiting
NCT06290193 — Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery · Phase 2 · recruiting
NCT06017557 — Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer · NA · recruiting
NCT04701645 — Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer · Phase 1 · recruiting
NCT04997096 — Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemothera · NA · recruiting

Other British Columbia Cancer Agency trials

Trials by the same sponsor.

NCT07295171 — HELP Study - Towards High Throughput and Efficient Long-axial PET With Oral [18F]FDG · NA · recruiting
NCT07291895 — High Dose Radiotherapy for Palliation (Hi-D) · NA · not yet recruiting
NCT06918951 — Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers · NA · recruiting
NCT07210749 — Radiotherapy 12Gy in 6 Fractions For Orbital Lymphoma · NA · not yet recruiting
NCT06835725 — Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prost · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06650709 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by British Columbia Cancer Agency
Last refreshed: 23 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06650709.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing